ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, announced the launch of “Do It For Future You,” a new multichannel campaign designed to inspire individuals to take control of their health today to better safeguard their future. The campaign…
GSK plc Sponsored ADR (LSE:GSK) is reshaping itself with a £1.9B cost-saving plan and £2.4B restructuring to move R&D to Cambridge, adopt AI and streamline ops while launching 25 late-stage trials by 2026, buoyed by Artemis-011 Phase III success and a $110M Relation Therapeutics AI tie-up.Previous…
RNS Number : 4331O GlaxoSmithKline Capital PLC 29 July 2026 Issued: 29 July 2026, London UKGlaxoSmithKline Capital plc publication of Interim Management Report 2026GlaxoSmithKline Capital plc (the "Company") today announced the publication on the GSK Group ("GSK") website, www.gsk.com*, of its…
GSK (GSK) Q2 2026: revenue £8.41B (+5% cc), core operating profit £2.8B (+7% cc), core EPS 50.5p (+9%), reported net profit £435M. Announced £1.9B annual savings target by 2029.GSK
RNS Number : 1990O GSK PLC 28 July 2026 Issued: 28 July 2026, London UKGSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK· Investment further integrates company into world-class ecosystem of biomedical research, patient care and academia· Catalyst to fuel collaborat…
RNS Number : 1879O GSK PLC 28 July 2026 Issued: 28 July 2026, London UKGSK's licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China· ARTEMIS-011, a phase III study conducted for China, met its primary endpoint of progression-free survival in relap…
RNS Number : 8172N GSK PLC 24 July 2026 GSK plc (the 'Company')Transaction notificationAbout GSKGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.Registered in England & Wales:No. 3888792Regis…
RNS Number : 8272N GSK PLC 24 July 2026 Issued: 24 July 2026, London UKAdmission to tradingIn conformity with PRM 1.6.4R, GSK plc notifies the market that ordinary shares of 31¼ pence each ('Ordinary Shares') have been admitted to trading as set out in the table below. The Ordinary Shares have…
RNS Number : 4741N GSK PLC 22 July 2026 Issued: 22 July 2026, London UKJideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer· Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally…
GSK halted camlipixant for refractory chronic cough after mixed Phase 3 results. Shares fell up to 4.5%. Company redirects focus to other programs, including oncology, for its 2031
GSK plc (LSE:GSK) reshapes its pipeline after halting camlipixant for refractory cough amid mixed Phase III results while completing the $10.6B Nuvalent buy to add three oncology assets, a move analysts say boosts long‑term growth as HIV slows; shares slipped ~1.7%.Previous Week Recap T…
RNS Number : 8181M GSK PLC 17 July 2026 Issued: 17 July 2026, London UKAudit tender conclusionGSK plc today announces that, after the conclusion of a competitive tender process led by the Audit & Risk Committee, the Board has decided to re-appoint Deloitte LLP (Deloitte) as GSK's external audit…
RNS Number : 8184M GSK PLC 17 July 2026 Issued: 17 July 2026, London UKGSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)GSK plc (LSE/NYSE: GSK) today provides an update on the CALM-1 and CALM-2 phase III clinical trials, which assesse…
RNS Number : 1370M GSK PLC 13 July 2026 GSK plc (the 'Company')Transaction notificationAbout GSKGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.Registered in England & Wales:No. 3888792Regis…
RNS Number : 7582L GSK PLC 09 July 2026 GSK plc (the 'Company')Transaction notificationAbout GSKGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.Registered in England & Wales:No. 3888792Regis…
RNS Number : 6957L GSK PLC 09 July 2026 Issued: 9 July 2026, London UKRoy Jakobs to join GSK Board as Non-Executive DirectorGSK plc (LSE/NYSE: GSK) has today announced that Roy Jakobs will join the Board of the Company as a Non-Executive Director from 13 July 2026.Mr Jakobs is currently Chief E…
Vertex Pharmaceuticals NASDAQ:VRTX has agreed to buy Crinetics Pharmaceuticals NASDAQ:CRNX for about $10 billion, expanding its reach beyond blood disorders and pain into rare endocrine diseases.The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical…
The UK's blue-chip FTSE 100 slipped on Wednesday, with healthcare and energy shares leading declines, as investors monitored the latest setback in U.S.-Iran talks.The internationally focused FTSE 100 index CURRENCYCOM:UK100 closed down 0.2%, while the mid-cap FTSE 250 FTSE:MCX jumped 1.4% to a one…
RNS Number : 2039K GSK PLC 29 June 2026 TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BN7SWP63Issuer NameGSK PLCUK or Non-UK IssuerUK2. Reason for NotificationAn acquisition or disposal of voting rights3. Details of person subject to the notification obligationN…
FRANKFURT (dpa-AFX) - The following investment banks issued recommendationson U.K. stocks this morning as follows:- BARCLAYS CUTS VICTREX PRICE TARGET TO 590 (610) PENCE - 'EQUAL WEIGHT'- BARCLAYS RAISES GSK PRICE TARGET TO 1900 (1800) PENCE - 'UNDERWEIGHT'- BARCLAYS RAISES SERCO GROUP PRICE TARGET…
